Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) ROCE % : 3.58% (As of Dec. 2023)

View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Taro Pharmaceutical Industries's annualized ROCE % for the quarter that ended in Dec. 2023 was 3.58%.

Taro Pharmaceutical Industries ROCE % Historical Data

The historical data trend for Taro Pharmaceutical Industries's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taro Pharmaceutical Industries ROCE % Chart

Taro Pharmaceutical Industries Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

17.27

14.80

-20.25

4.58

2.26

Taro Pharmaceutical Industries Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															0.30	7.09	-1.81	1.08	3.58

Taro Pharmaceutical Industries ROCE % Calculation

Taro Pharmaceutical Industries's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	39.466	/	( ( (2176.362 - 432.118)	+	(2135.513 - 385.548) )	/ 2 )
	=	39.466	/	( (1744.244	+	1749.965)	/ 2 )
	=	39.466	/	1747.1045
	=	2.26 %

Taro Pharmaceutical Industries's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	63.532	/	( ( (2119.473 - 361.488)	+	(2163.179 - 374.059) )	/ 2 )
	=	63.532	/	( ( 1757.985	+	1789.12 )	/ 2 )
	=	63.532	/	1773.5525
	=	3.58 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Taro Pharmaceutical Industries (NYSE:TARO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Taro Pharmaceutical Industries ROCE % Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TAL:Germany

Address

14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761

Website

https://www.taro.com

Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.

Executives

Sun Pharma Global Inc	10 percent owner
Sun Pharmaceutical Industries Ltd	10 percent owner, other: Affiliated Party	17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd.	10 percent owner	KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc	10 percent owner	FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403